Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Plada Infotech Services L Share Price

₹ 17.5 0.00 (0.00%)

Apr 15 2025 12:00 AM IT - Software NSE: PLADAINFO

Plada Infotech Services L Share Price Update

As of the latest trading session, Plada Infotech Services L share price is currently at 17.5, which is up by 0.00 from its previous closing. Today, the stock has fluctuated between 17.50 and 17.50. Over the past year, Plada Infotech Services L has achieved a return of -42.17 %. In the last month alone, the return has been -20.93 %. Read More...

Plada Infotech Services L Performance

Day Range

Low17.50 High17.50

17.50

52 Week Range

Low 16.00 High 35.00

17.50

Plada Infotech Services L Share Price

19492

210708

PLADAINFO

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

17.50 Prev. Close

17.50 Volume (Shares)

3000.00

Total traded value

.52

Upper Circuit

21.00 Lower Circuit

14.00

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Plada Infotech Services L Fundamentals

(Standalone)

Market Cap (Cr)	15.00
PE Ratio (TTM)	5.78
Book Value / Share	26.93
Beta	0.57

ROE	15.79%
EPS (TTM)	2.94
Dividend Yield	0.00%
Net Profit Qtr (Cr)	0.00

Plada Infotech Services L Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	MAR 2024 (Values in Cr)
Revenue	63.18
Operating Expense	60.83
Net Profit	2.52
Net Profit Margin (%)	3.98
Earnings Per Share (EPS)	3.50
EBITDA	5.33
Effective Tax Rate (%)	11.57

Particulars	MAR 2023 (Values in Cr)
Revenue	62.03
Operating Expense	60.12
Net Profit	2.48
Net Profit Margin (%)	3.99
Earnings Per Share (EPS)	4.14
EBITDA	5.12
Effective Tax Rate (%)	6.41

Particulars	MAR 2022 (Values in Cr)
Revenue	48.61
Operating Expense	47.21
Net Profit	1.13
Net Profit Margin (%)	2.32
Earnings Per Share (EPS)	56.59
EBITDA	4.38
Effective Tax Rate (%)	24.66

Particulars	MAR 2021 (Values in Cr)
Revenue	44.42
Operating Expense	43.48
Net Profit	0.72
Net Profit Margin (%)	1.62
Earnings Per Share (EPS)	723.53
EBITDA	3.63
Effective Tax Rate (%)	28.71

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	25.58
ROE %	17.99
ROCE %	16.70
Total Debt to Total Equity	1.05
EBITDA Margin	8.50

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	37.64
ROE %	36.82
ROCE %	21.01
Total Debt to Total Equity	2.69
EBITDA Margin	8.25

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	259.05
ROE %	23.76
ROCE %	18.00
Total Debt to Total Equity	4.02
EBITDA Margin	9.08

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	4084.40
ROE %	17.84
ROCE %	14.45
Total Debt to Total Equity	5.25
EBITDA Margin	8.33

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	3426.00
ROE %	34.99
ROCE %	16.57
Total Debt to Total Equity	5.80
EBITDA Margin	8.55

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	26.94
ROE %	15.79
ROCE %	15.90
Total Debt to Total Equity	0.97
EBITDA Margin	8.44

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	44.09
ROE %	32.72
ROCE %	20.08
Total Debt to Total Equity	2.26
EBITDA Margin	8.25

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	316.79
ROE %	19.58
ROCE %	17.43
Total Debt to Total Equity	3.21
EBITDA Margin	9.11

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	5203.98
ROE %	14.88
ROCE %	14.19
Total Debt to Total Equity	3.98
EBITDA Margin	8.35

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	4480.45
ROE %	32.43
ROCE %	21.32
Total Debt to Total Equity	3.53
EBITDA Margin	8.31

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	3.83
Total Assets	39.12
Total Liabilities	39.12
Total Equity	21.92
Share Outstanding	8574000
Price to Book Ratio	0.92
Return on Assets (%)	6.78
Return on Capital (%)	7.33

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	3.59
Total Assets	28.11
Total Liabilities	28.11
Total Equity	7.51
Share Outstanding	2000000
Price to Book Ratio	0.00
Return on Assets (%)	8.31
Return on Capital (%)	9.72

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	2.34
Total Assets	27.20
Total Liabilities	27.20
Total Equity	5.17
Share Outstanding	200000
Price to Book Ratio	0.00
Return on Assets (%)	4.03
Return on Capital (%)	4.79

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	2.20
Total Assets	27.60
Total Liabilities	27.60
Total Equity	4.07
Share Outstanding	10000
Price to Book Ratio	0.00
Return on Assets (%)	2.38
Return on Capital (%)	2.79

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	1.45
Total Assets	27.11
Total Liabilities	27.11
Total Equity	3.41
Share Outstanding	10000
Price to Book Ratio	0.00
Return on Assets (%)	4.37
Return on Capital (%)	5.08

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	3.31
Total Assets	39.51
Total Liabilities	39.51
Total Equity	23.09
Share Outstanding	8574000
Price to Book Ratio	0.92
Return on Assets (%)	6.38
Return on Capital (%)	6.75

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	3.09
Total Assets	28.01
Total Liabilities	28.01
Total Equity	8.81
Share Outstanding	2000000
Price to Book Ratio	0.00
Return on Assets (%)	8.86
Return on Capital (%)	9.79

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	2.04
Total Assets	27.28
Total Liabilities	27.28
Total Equity	6.33
Share Outstanding	200000
Price to Book Ratio	0.00
Return on Assets (%)	4.14
Return on Capital (%)	4.71

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	1.61
Total Assets	27.41
Total Liabilities	27.41
Total Equity	5.20
Share Outstanding	10000
Price to Book Ratio	0.00
Return on Assets (%)	2.63
Return on Capital (%)	2.95

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.69
Total Assets	26.86
Total Liabilities	26.86
Total Equity	4.48
Share Outstanding	10000
Price to Book Ratio	0.00
Return on Assets (%)	4.66
Return on Capital (%)	5.29

Particulars	MAR 2024 (Values in Cr)
Net Income	2.89
Cash from Operations	-3.35
Cash from Investing	-3.36
Cash from Financing	7.47
Net change in Cash	0.24
Free Cash Flow	-1.05

Particulars	MAR 2023 (Values in Cr)
Net Income	2.65
Cash from Operations	4.40
Cash from Investing	0.44
Cash from Financing	-3.46
Net change in Cash	1.03
Free Cash Flow	4.47

Particulars	MAR 2022 (Values in Cr)
Net Income	1.09
Cash from Operations	4.50
Cash from Investing	-0.24
Cash from Financing	-4.42
Net change in Cash	0.14
Free Cash Flow	4.50

Particulars	MAR 2021 (Values in Cr)
Net Income	0.65
Cash from Operations	4.31
Cash from Investing	-0.61
Cash from Financing	-2.70
Net change in Cash	0.74
Free Cash Flow	4.37

Particulars	MAR 2020 (Values in Cr)
Net Income	1.18
Cash from Operations	1.52
Cash from Investing	-9.84
Cash from Financing	9.33
Net change in Cash	0.71
Free Cash Flow	1.59

Particulars	MAR 2024 (Values in Cr)
Net Income	2.85
Cash from Operations	-0.79
Cash from Investing	-3.80
Cash from Financing	5.08
Net change in Cash	0.23
Free Cash Flow	2.45

Particulars	MAR 2023 (Values in Cr)
Net Income	2.65
Cash from Operations	3.19
Cash from Investing	0.67
Cash from Financing	-3.45
Net change in Cash	0.84
Free Cash Flow	3.26

Particulars	MAR 2022 (Values in Cr)
Net Income	1.49
Cash from Operations	4.71
Cash from Investing	0.05
Cash from Financing	-3.96
Net change in Cash	0.42
Free Cash Flow	4.71

Particulars	MAR 2021 (Values in Cr)
Net Income	1.00
Cash from Operations	2.53
Cash from Investing	0.39
Cash from Financing	-1.74
Net change in Cash	0.91
Free Cash Flow	2.59

Particulars	MAR 2020 (Values in Cr)
Net Income	1.69
Cash from Operations	4.24
Cash from Investing	-12.34
Cash from Financing	8.70
Net change in Cash	0.16
Free Cash Flow	4.29

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
ZENSAR TECHNOLOGIES LTD	634.30	22.27	3.88	14405.55	531.15 / 985.00
WIPRO LTD	239.80	20.25	3.08	251121.82	208.40 / 324.55
INFORMED TECHNOLOGIES INDIA LT	65.65	14.00	1.22	27.38	54.00 / 140.00
PCS TECHNOLOGY LTD.	29.99	52.61	1.40	62.83	23.00 / 44.88

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
ZENSAR TECHNOLOGIES LTD	634.30	25.68	5.19	14405.55	531.15 / 985.00
MIPCO SEAMLESS RINGS (GUJARAT)	37.38	0.00	-4.07	13.40	26.11 / 46.35
WIPRO LTD	239.80	24.27	3.97	251121.82	208.40 / 324.55
INFORMED TECHNOLOGIES INDIA LT	65.65	14.03	1.27	27.38	54.00 / 140.00

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 17.30
26 Days 19.60
10 Days 17.70
50 Days 21.80
12 Days 18.00
100 Days 24.70
20 Days 18.90
200 Days 29.00

17.00
PIVOT

First Resistance	17.00
Second Resistance	17.00
Third Resistance	17.00

First Support	17.00
Second Support	17.00
Third Support	17.00

RSI	37.75
MACD	-1.66
Commodity Channel Index (CCI)	-78.14

ADX	44.05
Williams % R	-78.02

Plada Infotech Services L Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

37.36 Promoter Holdings

62.63 FII

0.0 DII

0.0 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Shaileshkumar Damani	Shareholding of Promoter and Promoter Group	5070394.0	59.14
Mahesh Ahuja	Public Shareholding	600000.0	7.0
Anil Mahendra Kotak	Shareholding of Promoter and Promoter Group	300000.0	3.5
Krutika Shailesh Damani	Shareholding of Promoter and Promoter Group	12.0	0.0
Namrata Manish Damani	Shareholding of Promoter and Promoter Group	12.0	0.0
Deepak Ramchandra Kelkar	Shareholding of Promoter and Promoter Group	12.0	0.0
Anju Deepak Kelkar	Shareholding of Promoter and Promoter Group	12.0	0.0
Archana Shaileshkumar Damani	Shareholding of Promoter and Promoter Group	12.0	0.0
Manish Ganeshlal Damani	Shareholding of Promoter and Promoter Group	12.0	0.0

Plada Infotech Services L

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read